{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-069693","form_type":"8-K","ticker":"SYRE","cik":"0001636282","company_name":"Spyre Therapeutics, Inc.","filed_at":"2024-03-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.926253+00:00","generated_at":"2026-06-04T15:13:57.890172+00:00","sec_items":["1.01","5.03","3.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Spyre Therapeutics announces $180M private placement of convertible preferred stock","bullets":["Spyre raises ~$180M via PIPE: 121,625 Series B convertible preferred shares at $1,480 each.","Series B convertible into 4,865,000 common shares (40:1), subject to stockholder approval and beneficial ownership limits.","PIPE includes new and existing investors; expected close on March 20, 2024.","Proceeds to fund pipeline programs and extend cash runway well into 2027.","Authorized Series B shares increased from 150,000 to 271,625 via Certificate of Amendment."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-069693","json":"https://secwatch.observer/filing/0001193125-24-069693.json","markdown":"https://secwatch.observer/filing/0001193125-24-069693.md","text":"https://secwatch.observer/filing/0001193125-24-069693.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1636282/000119312524069693/0001193125-24-069693-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1636282/000119312524069693/d784263d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T15:13:57.890172+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"16863be5946a2957cf5734e035a13bf6f4d86bb5","claim":"Spyre Therapeutics, Inc.: Increased authorized shares of Series B Preferred Stock from 150,000 to 271,625 (effective 2024-03-18).","evidence_excerpt":"The Certificate of Amendment increases the number of authorized shares of the Company's Series B Preferred Stock from 150,000 to 271,625.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1636282/000119312524069693/0001193125-24-069693-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2024-03-18"}],"fact_type":"governance_change"},{"claim_id":"bbd133e7acd69c1634d3417d66f53e63677d3422","claim":"Spyre Therapeutics, Inc. entered into Securities Purchase Agreement with certain institutional and accredited investors valued at approximately $180.0 million (effective 2024-03-18).","evidence_excerpt":"On March 18, 2024, Spyre Therapeutics, Inc., a Delaware corporation (the \" Company \"), entered into a Securities Purchase Agreement (the \" Purchase Agreement \") for a private placement (the \" Private Placement \") with certain institutional and accredited investors (each, a \" Purchaser \" and collectively, the \" Purchasers \").","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1636282/000119312524069693/0001193125-24-069693-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain institutional and accredited investors"},{"label":"Value","value":"approximately $180.0 million"},{"label":"Effective","value":"2024-03-18"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}